163 In addition to the mentioned benefits, metformin also provides modest cardioprotection and improvement in various lipids and inflammatory marker profiles
Eligibility requirements for the GLP-1 Bridge Program include: Age 18 or older Enrollment in a Medicare Part D or Medicare Advantage Prescription Drug (MA-PD) plan One of the following BMI and health condition combinations: BMI 35 (regardless of other health conditions) BMI 30 with at least one of the following: heart failure with preserved ejection fraction (HFpEF), hypertension, or chronic kidney disease (CKD) BMI 27 with a history of pre-diabetes, myocardial infarction, stroke, or peripheral artery disease (PAD) The program covers the following GLP-1 receptor agonists: Foundayo (orforglipron) tablet, all dose strengths and formulations Wegovy (semaglutide) injections and tablets, all dose strengths and formulations Zepbound (tirzepatide) injections, only when prescribed as the KwikPen (single-dose vials and other single-dose pen formats are excluded) All prescriptions require prior authorization through Humana, which oversees clinical review to ensure adherence to the program's strict medical-necessity guidelines
Chang S-Y, Weber EJ, Sidorenko VS et al (2017) Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity
This decline may affect the bodys ability to protect cells and maintain optimal function
2) Oxidative stress: increased production of ROS and lipid peroxides due to impaired antioxidant defenses (e.g., reduced GPX4 activity) leads to oxidative damage and cell death
